Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M247Revenue $M18.8Net Margin (%)-522.7Altman Z-Score-3.8
Enterprise Value $M159EPS $-1.4Operating Margin %-425.0Piotroski F-Score4
P/E(ttm)--Beneish M-Score-2.2Pre-tax Margin (%)-522.7Higher ROA y-yN
Price/Book3.210-y EBITDA Growth Rate %-28.1Quick Ratio7.4Cash flow > EarningsY
Price/Sales11.35-y EBITDA Growth Rate %-16.1Current Ratio7.4Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-70.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-174.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M84.7ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with AGEN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AGENKen Fisher 2015-09-30 Buy $4.43 - $9.44
($7.57)
$ 2.92-61%New holding91,632
AGENGeorge Soros 2014-06-30 Sold Out $2.41 - $3.61
($2.94)
$ 2.92-1%Sold Out0
AGENFirst Eagle Investment 2014-06-30 Sold Out $2.41 - $3.61
($2.94)
$ 2.92-1%Sold Out0
AGENGeorge Soros 2014-03-31 Buy $2.64 - $5.1
($3.52)
$ 2.92-17%New holding102,200
AGENFirst Eagle Investment 2014-03-31 Buy $2.64 - $5.1
($3.52)
$ 2.92-17%New holding200,000
AGENRobert Bruce 2012-06-30 Buy 0.52%$4.84 - $6.9
($5.78)
$ 2.92-49%New holding233,515
AGENRobert Bruce 2010-12-31 Buy $5.34 - $6.48
($5.71)
$ 2.92-49%New holding233,517
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AGEN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ARMEN GARO HChairman & CEO 2015-12-29Sell219,576$4.59-36.38view
ARMEN GARO HChairman & CEO 2015-09-25Buy100,000$5.03-41.95view
Ballantyne Charles EvanCFO 2015-09-25Buy10,000$5.05-42.18view
Malik ShahzadDirector 2015-04-29Sell1,107,377$7.11-58.93view
QVT Associates GP LLC10% Owner 2015-01-09Sell2,343,630$5.31-45.01view
Wentworth KerryVP, Clinical, Reg & Qual 2014-02-26Sell5,000$5-41.6view
Malik ShahzadDirector 2014-02-12Sell0$0-41.6view
QVT Associates GP LLC10% Owner 2014-02-05Sell0$0-41.6view
Valentine KarenVP General Counsel 2014-01-23Sell2,850$3.5-16.57view
Baysal OzerChief Business Officer 2013-06-13Sell0$0-16.57view

Quarterly/Annual Reports about AGEN:

News about AGEN:

Articles On GuruFocus.com
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine Jul 25 2014 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 2,000 Shares Sep 14 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,520 Shares Jul 28 2010 

More From Other Websites
Agenus (AGEN) Catches Eye: Stock Adds 8.8% in Session Jan 22 2016
Agenus (AGEN) Stock Surges After FDA Approves Investigational New Drug Application Jan 21 2016
4 Nasdaq Stocks That Are Trading Higher Today Jan 21 2016
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 21 2016
Agenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and... Jan 21 2016
Agenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and... Jan 21 2016
Agenus Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 14 2016
Agenus Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 14 2016
Biotechnology Equity Movers and Shakers -- Agenus, Xenoport, Akebia Therapeutics, and Northwest... Jan 11 2016
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 04 2016
Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition Jan 04 2016
Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition Jan 04 2016
Agenus Acquires PhosImmune, Adds Cancer Neoantigens Dec 28 2015
Technical Coverage on Biotechnology Stocks - Agenus, Progenics Pharma, Arrowhead Research, and... Dec 28 2015
Traders Look to Upside - New Reports on Agenus, Beneficial Bancorp, Healthways, and Computer Task... Dec 28 2015
Agenus, Inc. breached its 50 day moving average in a Bullish Manner : December 25, 2015 Dec 25 2015
Agenus Acquires PhosImmune with a Novel Class of Cancer Neoantigens Dec 23 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK